JDRF applauds the U.S. Food and Drug Administration’s (FDA) approval of the first interchangeable biosimilar insulin product, Semglee® (insulin glargine-yfgn) , for those living with type 1 and type 2 diabetes.   

This is a step forward for the entire diabetes community as the interchangeable designation broadens the treatment options for individuals living with diabetes. 

JDRF will continue to drive long-term efforts and push for action from manufacturers, health plans, employers, and the government to lower the cost of insulin. 

-JDRF International